Thyroid and Glucose and Energy Metabolism
Thyroid Diseases
Bottom Line
View on ClinicalTrials.gov: NCT00106119 ↗Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Liothyronine and Levothyroxine (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Primary completion
- Nov 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase |
7.26 | — |
| PRIMARY Insulin-mediated Glucose Disposal Rate at Liothyronine Treatment Phase |
7.37 | — |
| SECONDARY Total Cholesterol at Levothyroxine Treatment Phase |
196 | — |
| SECONDARY Total Cholesterol at Liothyronine Treatment Phase |
174 | — |
| SECONDARY Triglycerides at Levothyroxine Treatment Phase |
152 | — |
| SECONDARY Triglycerides at Liothyronine Treatment Phase |
144 | — |
| SECONDARY Resting Energy Expenditure at Levothyroxine Treatment Phase |
1201 | — |
| SECONDARY Resting Energy Expenditure at Liothyronine Treatment Phase |
1177 | — |
| SECONDARY Left Ventricle Mass Index at Levothyroxine Treatment Phase |
71 | — |
| SECONDARY Left Ventricle Mass Index at Liothyronine Treatment Phase |
71 | — |
| SECONDARY Apolipoprotein A-I at Levothyroxine Treatment Phase |
152 | — |
| SECONDARY Apolipoprotein A-I at Liothyronine Treatment Phase |
144 | — |
| SECONDARY Apolipoprotein B at Levothyroxine Treatment Phase |
87 | — |
| SECONDARY Apolipoprotein B at Liothyronine Treatment Phase |
72 | — |
Summary
Eligibility Criteria
- INCLUSION CRITERIA:
Age greater than or equal to 18 years, male or female.
History of total or near total thyroidectomy or hypothyroidism on replacement therapy.
For non-thyroidectomized patients, at least three-year history of replacement therapy (at least 1.2 mcg/Kg LT4/body weight), and less than 5% uptake at 24H on (123)I thyroid scan while on replacement therapy.
Written informed consent.
EXCLUSION CRITERIA
BMI less than or equal to 20 or greater than or equal to 30 kg/m(2).
Metastatic thyroid cancer or history of thyroid cancer with high risk of recurrence requiring suppressive thyroid hormone therapy (Singer 1996).
Significant thyroid residual greater than 1 mL as measured by ultrasound (limited to thyroidectomized patients) or greater than 5 percent uptake at 24H on (123)I thyroid scan while on replacement therapy (limited to hypothyroid patients not undergone total thyroidectomy).
History or symptoms compatible with cardiovascular disease, including paroxysmal supraventricular tachycardia, atrial fibrillation, syncopal episodes or use of prescription medications for heart conditions, including antihypertensives.
Allergy to lidocaine, isoproterenol, TRH, levothyroxine, liothyronine, Tylenol #3, oxycodone, nitroglycerin.
Pregnancy or unwillingness to use non-hormonal contraception during the study.
Breastfeeding
Use of hormonal contraceptives or estrogen replacement therapy.
Use of tobacco (smoking, chewing) for the two weeks preceding the hospital admissions (metabolic testing)
Diabetes mellitus, either type I or II.
Hypercholesterolemia (serum levels greater than or equal to 240 mg/dL), hypertriglyceridemia (plasma levels greater than or equal to 220 mg/dL) and/or use of antilipemic therapy.
Liver disease or ALT serum level greater than two fold the upper laboratory reference limit.
Renal insufficiency or estimated creatinine clearance less than or equal to 50 mL/min.
Use of medications/supplements/alternative therapies known to alter thyroid function.
Current history or symptoms compatible with psychosis including major depression (including history of hospitalization for depression, history of attempted suicide, history of suicidal ideation).
Use of antipsychotic medications
History of drug or alcohol abuse within the last 5 years; current use of drugs or alcohol (CAGE greater than 3).
Keloid formation (relative to skeletal muscle and subcutaneous adipose tissue biopsies).
Current or previous clinically significant (requiring medical/surgical intervention) extrathyroidal manifestations of autoimmune thyroid disease (dermopathy, ophthalmopathy, arthropathy).
Data sourced from ClinicalTrials.gov (NCT00106119). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.